Academic Bibliography

Search 200 years of publications by Ghent University researchers.

em. prof. dr. Geert Leroux-Roels

Faculty of Medicine and Health Sciences > Department of Diagnostic Sciences

ORCID iD: 0000-0001-5968-2542

Add to list
- Journal Article
- A1
- open access
A novel carbohydrate fatty-acid monosulphate ester, squalane-in-water adjuvant is safe and enhances inactivated influenza vaccine immunogenicity in older adults

Valentino D'Onofrio (UGent) , Bart Jacobs (UGent) , Azhar Alhatemi (UGent) , Simon De Gussem (UGent) , Marjolein Verstraete (UGent) , Sharon Porrez (UGent) , Anthony Willems (UGent) , Fien De Boever (UGent) , Gwenn Waerlop (UGent) , Geert Leroux-Roels (UGent) , et al.

(2025) VACCINES. 13(9).
Add to list
- Journal Article
- A1
- open access
AS04 drives superior cross-protective antibody response by increased NOTCH signaling of dendritic cells and proliferation of memory B cells

Valentino D'Onofrio (UGent) , Ana Carolina Santana, Marthe Pauwels, Gwenn Waerlop (UGent) , Anthony Willems (UGent) , Fien De Boever (UGent) , Martin Müller, Peter Sehr, Tim Waterboer, Isabel Leroux-Roels (UGent) , et al.

(2025) FRONTIERS IN IMMUNOLOGY. 16.
Add to list
- Journal Article
- A1
- open access
Evaluation of safety, immunogenicity and cross-reactive immunity of OVX836, a nucleoprotein-based universal influenza vaccine, in older adults

Bart Jacobs, Isabel Leroux-Roels (UGent) , Jacques Bruhwyler, Nicola Groth, Gwenn Waerlop (UGent) , Yorick Janssens (UGent) , Jessika Tourneur, Fien De Boever (UGent) , Azhar Alhatemi (UGent) , Philippe Moris, et al.

(2024) VACCINES. 12(12).
Add to list
- Journal Article
- A1
- open access
Safety and immunogenicity of a carbohydrate fatty acid monosulphate ester adjuvant combined with a low-dose quadrivalent split-virion inactivated influenza vaccine : a randomised, observer-blind, active-controlled, first-in-human, phase 1 study

Valentino D'Onofrio (UGent) , Sharon Porrez (UGent) , Bart Jacobs (UGent) , Azhar Alhatemi (UGent) , Fien De Boever (UGent) , Gwenn Waerlop (UGent) , Els Michels, Francesca Vanni, Alessandro Manenti, Geert Leroux-Roels (UGent) , et al.

(2024) VACCINES. 12(9).
Add to list
- Journal Article
- A1
- open access
Safety and immunogenicity of the live-attenuated hRVFV-4s vaccine against Rift Valley fever in healthy adults : a dose-escalation, placebo-controlled, first-in-human, phase 1 randomised clinical trial

Isabel Leroux-Roels (UGent) , Chittappen Kandiyil Prajeeth, Amare Aregay, Niranjana Nair, Guus F Rimmelzwaan, Albert D M E Osterhaus, Simone Kardinahl, Sabrina Pelz, Stephan Bauer, Valentino D'Onofrio (UGent) , et al.

(2024) LANCET INFECTIOUS DISEASES. 24(11). p.1245-1253
Add to list
- Journal Article
- A1
- open access
Immune responses in healthy adults elicited by a bivalent norovirus vaccine candidate composed of GI.4 and GII.4 VLPs without adjuvant

Gwenn Waerlop (UGent) , Yorick Janssens (UGent) , Bart Jacobs (UGent) , Franziska Jarczowski, André Diessner, Geert Leroux-Roels (UGent) , Victor Klimyuk, Isabel Leroux-Roels (UGent) and Frank Thieme

(2023) FRONTIERS IN IMMUNOLOGY. 14.
Add to list
- Journal Article
- A1
- open access
Immunogenicity, safety, and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate : a randomised, double-blind, placebo-controlled, phase 2a trial

Isabel Leroux-Roels (UGent) , Paul Willems, Gwenn Waerlop (UGent) , Yorick Janssens (UGent) , Jessika Tourneur, Fien De Boever (UGent) , Jacques Bruhwyler, Azhar Alhatemi (UGent) , Bart Jacobs (UGent) , Florence Nicolas, et al.

(2023) LANCET INFECTIOUS DISEASES. 23(12). p.1360-1369
Add to list
- Journal Article
- A1
- open access
Human immunity and susceptibility to influenza A(H3) viruses of avian, equine, and swine origin

Elien Vandoorn, Wojciech Stadejek (UGent) , Isabel Leroux-Roels (UGent) , Geert Leroux-Roels (UGent) , Anna Parys and Kristien Van Reeth (UGent)

(2023) EMERGING INFECTIOUS DISEASES. 29(1). p.98-109
Add to list
- Journal Article
- A1
- open access
Double-blind, placebo-controlled, dose-escalating study evaluating the safety and immunogenicity of an epitope-specific chemically defined nanoparticle RSV vaccine

Isabel Leroux-Roels (UGent) , Jacques Bruhwyler, Lilli Stergiou, Mark Sumeray, Jasper Joye, Cathy Maes, Paul-Henri Lambert and Geert Leroux-Roels (UGent)

(2023) VACCINES. 11(2).
Add to list
- Journal Article
- A1
- open access
A human monoclonal antibody against HBsAg for the prevention and treatment of chronic HBV and HDV infection

Rani Burm, Freya Van Houtte (UGent) , Lieven Verhoye (UGent) , Ahmed Atef Ahmed Abouzeid Mesalam (UGent) , S Ciesek, P Roingeard, H Wedemeyer, Geert Leroux-Roels (UGent) and Philip Meuleman (UGent)

(2023) JHEP REPORTS. 5(3).

1
2
3
4
…
39
40

Next →